China's first case of transgenic cows

The R&D team led by Academician Li Ning of China Agricultural University cooperated with Beijing Jipulin Biotech Co., Ltd. and Beijing Kerun Weide Biotech Co., Ltd., and was successfully born at a transgenic animal experimentation base in Beijing. The "CD20 antibody gene" GM cow, the GM cow had a birth weight of 38 kg and was in good health.

The human CD20 monoclonal antibody is currently a special drug for treating malignant tumors such as B lymphoma. The human CD20 antibody currently produced by mammalian cell culture is the first anti-tumor monoclonal antibody drug approved by the US FDA, and its annual global sales reach more than 3 billion US dollars. However, such human CD20 antibody drugs are expensive to produce, expensive, and require $16,000 for a course of treatment (injection four times), which is a huge burden for most patients.

Academician Li Ning's R&D team's project is to obtain transgenic cow's mammary gland bioreactor through transgenic technology. The milk of the transgenic cow contains human CD20 monoclonal antibody. Through the purification of this monoclonal antibody, a cancer specific drug can be prepared and the production cost can be reduced to One-tenth of the original is expected to open up a new pathway for the production of monoclonal antibodies, which will be a boon to cancer patients such as B-lymphoma patients worldwide.